7AQJ

Target information

RCSB PDB
7AQJ
Title
Structure of SARS-CoV-2 Main Protease bound to Triglycidyl isocyanurate.
Method
X-RAY DIFFRACTION
Resolution
2.59
Classification
PEPTIDE BINDING PROTEIN
Organism
Severe acute respiratory syndrome coronavirus 2
Protein
Replicase polyprotein 1ab (P0DTD1)    Looking for covalent inhibitors of this target ?
Year
2020
Publication Title
X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease.
Abstract

The coronavirus disease (COVID-19) caused by SARS-CoV-2 is creating tremendous human suffering. To date, no effective drug is available to directly treat the disease. In a search for a drug against COVID-19, we have performed a high-throughput X-ray crystallographic screen of two repurposing drug libraries against the SARS-CoV-2 main protease (M pro ), which is essential for viral replication. In contrast to commonly applied X-ray fragment screening experiments with molecules of low complexity, our screen tested already approved drugs and drugs in clinical trials. From the three-dimensional protein structures, we identified 37 compounds that bind to M pro In subsequent cell-based viral reduction assays, one peptidomimetic and six non-peptidic compounds showed antiviral activity at non-toxic concentrations. We identified two allosteric binding sites representing attractive targets for drug development against SARS-CoV-2.

External Link
RCSB PDB





Ligand information

HET
S7H
Chain ID
A
HET Number
401
Molecular Formula
C12H15N3O6
Structure
2D structure
IUPAC Name
1,3,5-tris(oxiran-2-ylmethyl)-1,3,5-triazinane-2,4,6-trione
InChI
InChI=1S/C12H15N3O6/c16-10-13(1-7-4-19-7)11(17)15(3-9-6-21-9)12(18)14(10)2-8-5-20-8/h7-9H,1-6H2
InChI Key
OUPZKGBUJRBPGC-UHFFFAOYSA-N
Canonical SMILES
O=c1n(CC2CO2)c(=O)n(CC2CO2)c(=O)n1CC1CO1
Bioactivity data
CI006842

Covalent Binding

Warhead
Epoxide
Reaction Mechanism
Epoxide Opening
Residue
CYS : 145
Residue Chain
A
Interactions
Pharmacophore Model